Table 2.

Relationships between Kallistatin Levels and Variables of Interest for All HIV-infected Subjects.

A. Correlations between Kallistatin Levels and Variables of Interest
Variable	Baseline	Changes over 24 Weeks
Markers of Inflammation and Coagulation
hsCRP	R = −0.29; P = 0.0005	R = −0.15; P = 0.08
IL-6	R = −0.23; P = 0.007	R = −0.19; P = 0.03
sTNFR-I	R = −0.12; P = 0.18	R = −0.09; P = 0.31
sTNFR-II	R = −0.77; P = 0.38	R = −0.06; P = 0.49
sVCAM-1	R = 0.03; P = 0.77	R = −0.86; P = 0.32
sICAM-1	R = −0.004; P = 0.96	R = 0.04; P = 0.65
D-dimer	R = −0.8; P = 0.36	R = 0.05; P = 0.57
Fibrinogen	R = −0.23; P = 0.007	R = −0.05; P = 0.54
Markers of Subclinical Vascular Disease
CCA IMT	R = −0.09; P = 0.31	N/A
FMD	R = 0.09; P = 0.30	N/A
Demographics, Clinical, and Metabolic Parameters
Age	R = −0.12; P = 0.18	N/A
Body mass index	R = 0.04; P = 0.65	R = 0.20; P = 0.82
Systolic BP	R = 0.08; P = 0.34	R = 0.07; P = 0.43
Diastolic BP	R = 0.07; P = 0.39	R = −0.04; P = 0.64
LDL cholesterol	R = −0.03; P = 0.72	R = 0.1; P = 0.90
HDL cholesterol	R = −0.06; P = 0.47	R = −0.90; P = 0.31
Triglycerides	R = 0.13; P = 0.14	R = 0.18; P = 0.04
HOMA-IR	R = 0.18; P = 0.04	R = 0.09; P = 0.28
HIV Variables
CD4+ cell count	R = −0.12; P = 0.16	N/A
Nadir CD4+ cell count	R = −0.01; P = 0.91	N/A
HIV-1 RNA level*	R = 0.07; P = 0.72	N/A
HIV duration	R = −0.03; P = 0.77	N/A
NRTI duration	R = −0.02; P = 0.08	N/A
PI duration	R = 0.08; P = 0.41	N/A
NNRTI duration	R = 0.004; P = 0.97	N/A
B. Differences in Kallistatin Levels in Sub-groups Based on Dichotomous Variables
Variable	Kallistatin Level, μg/mL	P
CAC = 0	28.6 (18.7, 42.1)	0.84
CAC >0	28.4 (19.7, 38.0)
Detectable HIV-1 RNA	28.5 (20.1, 40.4)	0.58
Undetectable HIV-1 RNA	28.3 (16.7, 34.0)
Male sex	28.3 (19.7, 37.5)	0.31
Female sex	32.5 (17.0, 53.4)
Black race	27. (17.9, 39.5)	0.42
Non-black race	30.5 (22.7, 40.0)
Current smoker	26.7 (19.5, 38.8)	0.72
Current non-smoker	29.7 (19.2, 41.2)

hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; sTNFR-I, soluble tumor necrosis factor receptor-I; sTNFR-II, soluble tumor necrosis factor receptor-II; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intracellular adhesion molecule-1; CCA IMT, common carotid artery intima-media thickness; FMD, flow-mediated vasodilation; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; NRTI, nucleoside/nucleotide analogue reverse transcriptase inhibitor; PI, protease inhibitor; NNRTI, non-nucleoside/nucleotide analogue reverse transcriptase inhibitor; CAC, coronary artery calcium